Dongbo Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dongbo Chen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Hongsong Chen
Peking University People’s Hospital, Beijing, China
3 shared publications Liying Ren
Laboratory of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, No. 15, Lequn Road, Xiufeng District, Guilin, 541001, Guangxi, China
2 shared publicationsBigeng Zhao
Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China
1 shared publication- Feng Liu
Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People’s Hospital, Beijing 100044, China
1 shared publication - Fengmin Lu
Department of Microbiology and Infectious Disease Center School of Basic Medical Sciences Peking University Health Science Center Beijing China
1 shared publication - Haibo Wang
Clinical Research Institute, Institute of Advanced Clinical Medicine, Peking University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 5 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1855
Development of a nomogram for predicting microvascular invasion in patients with hepatocellular carcinoma
Preoperative diagnosis of microvascular invasion (MVI) is difficult for patients with hepatocellular carcinoma (HCC). The aim of this study was to develop and validate a nomogram to predict the risk of MVI before surgery. A total of 661 HCC patients who underwent curative resection were included in the study. Independent risk factors were identified by univariate/multivariate analyses and were built into a nomogram to estimate the risk of MVI. The receiver operating characteristic (ROC) curve, concordance index (c-index), calibration curve and decision curve analysis were used to evaluate the predictive performance of the models. Prealbumin, gamma-glutamyl transpeptidase, alpha-fetoprotein level, and tumor size were found to be independent risk factors for MVI and formed the basis of the nomogram. The area under the ROC curve (AUC) of the nomogram for predicting MVI was 0.775 (C-index of 0.781) in the training cohort, 0.787 (C-index of 0.785) in the validation cohort, and 0.789 (C-index of 0.790) in the external validation cohort. The nomogram exhibited favorable calibration performance, and decision curve analysis demonstrated that the nomogram has clinical value. We developed a new nomogram that used basic clinical and laboratory variables to predict the probability of MVI before surgery for HCC patients. This nomogram can help clinicians choose appropriate treatment procedures.
- 5 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1855
Open AccessDevelopment of a nomogram for predicting microvascular invasion in patients with hepatocellular carcinoma
Preoperative diagnosis of microvascular invasion (MVI) is difficult for patients with hepatocellular carcinoma (HCC). The aim of this study was to develop and validate a nomogram to predict the risk of MVI before surgery. A total of 661 HCC patients who underwent curative resection were included in the study. Independent risk factors were identified by univariate/multivariate analyses and were built into a nomogram to estimate the risk of MVI. The receiver operating characteristic (ROC) curve, concordance index (c-index), calibration curve and decision curve analysis were used to evaluate the predictive performance of the models. Prealbumin, gamma-glutamyl transpeptidase, alpha-fetoprotein level, and tumor size were found to be independent risk factors for MVI and formed the basis of the nomogram. The area under the ROC curve (AUC) of the nomogram for predicting MVI was 0.775 (C-index of 0.781) in the training cohort, 0.787 (C-index of 0.785) in the validation cohort, and 0.789 (C-index of 0.790) in the external validation cohort. The nomogram exhibited favorable calibration performance, and decision curve analysis demonstrated that the nomogram has clinical value. We developed a new nomogram that used basic clinical and laboratory variables to predict the probability of MVI before surgery for HCC patients. This nomogram can help clinicians choose appropriate treatment procedures.
- Open Access
- 24 July 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1208165
Prognosis and therapeutic benefits prediction based on NK cell marker genes through single-cell RNA-seq with integrated bulk RNA-seq analysis for hepatocellular carcinoma
Tumor-infiltrating immune cells greatly participate in regulating tumorigenesis and metastasis of hepatocellular carcinoma (HCC). Natural killer cell, as an important role of innate immunity, plays an indispensable role in antitumor immunity and regulate tumor development. In this study, we firstly identified 251 NK cell marker genes of HCC based on single-cell RNA sequencing data. Subsequently, an NK cell marker genes-related prognostic signature (NKPS) was developed in the cancer genome atlas (TCGA) cohort for risk stratification and prognosis prediction. The predictive value of the NKPS in prognosis was well validated in different clinical subgroups and three external datasets (ICGC-LIHC cohort, GSE14520 cohort and Guilin cohort). Moreover, multivariate analysis revealed the independent prognostic value of NKPS for OS in HCC. Further functional analysis indicated the NKPS was associated with basic cellular processes, that may contribute to the development and progression of HCC. Thereafter, immune characteristics as well as the therapeutic benefits in NKPS risk score-defined subgroups were analyzed. Patients with low-risk score exhibited immune-active status, manifested as higher immune scores, more infiltration of CD8+ T cells and macrophage M1, and higher T-cell receptor (TCR) richness and diversity. Remarkably, the NKPS was negatively correlated with immunotherapy response-related signatures. In addition, the low-risk group exhibited significantly improved therapeutic benefits, either from immunotherapy or traditional chemotherapy and target therapy. Overall, the NKPS showed an excellent predictive value for prognosis and therapeutic responses for HCC, which might also provide novel insights into better HCC management strategies.
- 24 July 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1208165
Open AccessPrognosis and therapeutic benefits prediction based on NK cell marker genes through single-cell RNA-seq with integrated bulk RNA-seq analysis for hepatocellular carcinoma
Tumor-infiltrating immune cells greatly participate in regulating tumorigenesis and metastasis of hepatocellular carcinoma (HCC). Natural killer cell, as an important role of innate immunity, plays an indispensable role in antitumor immunity and regulate tumor development. In this study, we firstly identified 251 NK cell marker genes of HCC based on single-cell RNA sequencing data. Subsequently, an NK cell marker genes-related prognostic signature (NKPS) was developed in the cancer genome atlas (TCGA) cohort for risk stratification and prognosis prediction. The predictive value of the NKPS in prognosis was well validated in different clinical subgroups and three external datasets (ICGC-LIHC cohort, GSE14520 cohort and Guilin cohort). Moreover, multivariate analysis revealed the independent prognostic value of NKPS for OS in HCC. Further functional analysis indicated the NKPS was associated with basic cellular processes, that may contribute to the development and progression of HCC. Thereafter, immune characteristics as well as the therapeutic benefits in NKPS risk score-defined subgroups were analyzed. Patients with low-risk score exhibited immune-active status, manifested as higher immune scores, more infiltration of CD8+ T cells and macrophage M1, and higher T-cell receptor (TCR) richness and diversity. Remarkably, the NKPS was negatively correlated with immunotherapy response-related signatures. In addition, the low-risk group exhibited significantly improved therapeutic benefits, either from immunotherapy or traditional chemotherapy and target therapy. Overall, the NKPS showed an excellent predictive value for prognosis and therapeutic responses for HCC, which might also provide novel insights into better HCC management strategies.
- Open Access
IGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor
PD-(L)1 inhibitor could improve the survival of locally advanced esophageal cancer (ESCA) patients, but we cannot tailor the treatment to common biomarkers. WNT signaling activation was associated with primary resistance to immunotherapy. In this study, we used our two clinical cohorts (BJCH n = 95, BJIM n = 21) and three public cohorts to evaluate and verify a new immunotherapeutic biomarker based on WNT signaling in ESCA patients. Our findings showed that WNT signaling-related genes stratified TCGA patients into Cluster 1, 2, and 3, among which, Cluster 3 had the worst prognosis. The most up- and down-regulated genes in Cluster 3 were IGFBP1 and WNT3A. Further analysis validated that IGFBP1hiWNT3Alo ESCA patients had significantly poor RFS and OS in the TCGA and BJCH cohorts. Interestingly, IGFBP1hiWNT3Alo patients had a good response and prognosis with immunotherapy in three independent cohorts, exhibiting better predictive value than PD-L1 expression (signature AUC = 0.750; PD-L1 AUC = 0.571). Moreover, IGFBP1hiWNT3Alo patients may benefit more from immunotherapy than standard treatment (p = 0.026). Immune cell infiltration analysis revealed a significant increase in DC infiltration in IGFBP1hiWNT3Alo patients post-immunotherapy (p = 0.022), which may enhance immune response. The IGFBP1hiWNT3Alo signature could predict patients who benefited from PD-(L)1 inhibitor treatment and may serve as a biomarker in ESCA.
Open AccessIGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor
PD-(L)1 inhibitor could improve the survival of locally advanced esophageal cancer (ESCA) patients, but we cannot tailor the treatment to common biomarkers. WNT signaling activation was associated with primary resistance to immunotherapy. In this study, we used our two clinical cohorts (BJCH n = 95, BJIM n = 21) and three public cohorts to evaluate and verify a new immunotherapeutic biomarker based on WNT signaling in ESCA patients. Our findings showed that WNT signaling-related genes stratified TCGA patients into Cluster 1, 2, and 3, among which, Cluster 3 had the worst prognosis. The most up- and down-regulated genes in Cluster 3 were IGFBP1 and WNT3A. Further analysis validated that IGFBP1hiWNT3Alo ESCA patients had significantly poor RFS and OS in the TCGA and BJCH cohorts. Interestingly, IGFBP1hiWNT3Alo patients had a good response and prognosis with immunotherapy in three independent cohorts, exhibiting better predictive value than PD-L1 expression (signature AUC = 0.750; PD-L1 AUC = 0.571). Moreover, IGFBP1hiWNT3Alo patients may benefit more from immunotherapy than standard treatment (p = 0.026). Immune cell infiltration analysis revealed a significant increase in DC infiltration in IGFBP1hiWNT3Alo patients post-immunotherapy (p = 0.022), which may enhance immune response. The IGFBP1hiWNT3Alo signature could predict patients who benefited from PD-(L)1 inhibitor treatment and may serve as a biomarker in ESCA.
- Open Access
Epidemic prevention and control measures in China significantly curbed the epidemic of COVID-19 and influenza
At the end of 2019, an outbreak of unknown pathogen pneumonia occurred in China, then it was named corona virus disease 2019 (COVID-19). With the rapid spread of COVID-19, a series of strict prevention and control measures were implemented to cut the spread of the epidemic. Influenza as a respiratory tract infection disease as COVID-19 might also be controlled. To assess the effects, we used the total passenger numbers sent in mainland China from 2018 to 2020 and the daily number of railway passenger (DNRP) flow in 2020 during Spring Festival travel rush to reflect the population movement and further to analyze newly and cumulative confirmed COVID-19 and influenza. We found that with implementing the series measures on COVID-19, not only COVID-19, but also influenza mitigated in China. The prevention and control measures for COVID-19 might be used in controlling respiratory tract diseases, and reducing the national health economic burden. When other countries issue measures on COVID-19 and influenza, they should consider adopting more aggressive epidemic prevention and control strategies.
Open AccessEpidemic prevention and control measures in China significantly curbed the epidemic of COVID-19 and influenza
At the end of 2019, an outbreak of unknown pathogen pneumonia occurred in China, then it was named corona virus disease 2019 (COVID-19). With the rapid spread of COVID-19, a series of strict prevention and control measures were implemented to cut the spread of the epidemic. Influenza as a respiratory tract infection disease as COVID-19 might also be controlled. To assess the effects, we used the total passenger numbers sent in mainland China from 2018 to 2020 and the daily number of railway passenger (DNRP) flow in 2020 during Spring Festival travel rush to reflect the population movement and further to analyze newly and cumulative confirmed COVID-19 and influenza. We found that with implementing the series measures on COVID-19, not only COVID-19, but also influenza mitigated in China. The prevention and control measures for COVID-19 might be used in controlling respiratory tract diseases, and reducing the national health economic burden. When other countries issue measures on COVID-19 and influenza, they should consider adopting more aggressive epidemic prevention and control strategies.
- 1 April 2019
- Published by Elsevier in Journal of Hepatology
- Vol. 70 (1) , e357-E357
THU-450-RFX5 promotes hepatocellular carcinoma progression via transcriptional activation of YWHAQ
- 1 April 2019
- Published by Elsevier in Journal of Hepatology
- Vol. 70 (1) , e357-E357
THU-450-RFX5 promotes hepatocellular carcinoma progression via transcriptional activation of YWHAQ